Abstract:Background Previous genome-wide association studies (GWAS) have identified several risk genes for stroke; however, it remains unclear how they confer risk for the disease. We conducted an integrative analysis to identify candidate genes for stroke and stroke subtypes by integrating blood-derived multi-omics data with genetic data. Method We systematically integrated the latest stroke GWAS database (73,652 patients and 1,234,808 controls) with human plasma proteomes (N=7,213) and performed proteome-wide association studies (PWAS), Mendelian randomization (MR), Bayesian colocalization analysis, and transcriptome-wide association study (TWAS) to prioritize genes that associate the risk of stroke and its subtypes with their expression and protein abundance in plasma. Cell-type specificity and functional enrichment analysis using single-cell RNA sequencing (scRNA-seq) and Gene Ontology (GO) databases were then performed to select target genes. A two-step MR analysis was followed to explore the potential mechanisms. Results We found that the protein abundance of seven genes ( MMP12, F11, SH3BGRL3, ENGASE, SCARA5, SWAP70, and SPATA20 ) in the plasma was associated with stroke and its subtypes, with six genes ( MMP12, F11, SH3BGRL3, SCARA5, SWAP70, and SPATA20 ) causally related with stroke and its subtypes (P < 0.05/proteins identified for PWAS; P < 0.05/8 for MR; posterior probability of hypothesis 4 ≥ 75 % for Bayesian colocalization). The effect of F11, SH3BGRL, SPATA20, and SWAP70 on each subtype was mediated by Factor XI inhibitors (FXI), atrial fibrillation, T2D, and SBP respectively (p<0.05). We also found that SCARA5 and SWAP70 were related to stroke and ischemic stroke at the transcriptome level. Conclusions Our present proteomic findings have identified new causal genes in the pathogenesis of stroke, which may offer potential future therapeutic targets for stroke prevention. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was partially supported by grants from the National Natural Science Foundation of China (No. 81400979 and 81870931), the SanHang Program of the Naval Medical University, and the ?Climbing? program of Changhai Hospital. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: NONE I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data in the manuscript is truly usable

Identification of novel proteins for lacunar stroke by integrating genome-wide association data and human brain proteomes

Identification of Glycoproteins in Human Cerebrospinal Fluid with a Complementary Proteomic Approach

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

Identifying causal genes for stroke via integrating the proteome and transcriptome from brain and blood

Integrative analysis of transcriptome-wide association study and gene expression profiling identifies candidate genes associated with stroke.

Identification of novel proteins for coronary artery disease by integrating GWAS data and human plasma proteomes

Identification of Pleiotropic Genes Between Risk Factors of Stroke by Multivariate Metacca Analysis

Novel insight into the etiology of ischemic stroke gained by integrative transcriptome-wide association study

Novel insight into the etiology of ischemic stroke gained by integrative multiome-wide association study

Identification of Potential Therapeutic targets for Stroke and Its Subtypes by Integrating Proteomes and Genetics from Human Plasma

Identifying novel risk genes in intracranial aneurysm by integrating human proteomes and genetics

Genome-wide Association Studies in Neurology.

Genome-wide Association Analysis to Search for New Loci Associated with Stroke Risk in Northwestern Chinese Population.

Plasma Proteomes and Genome-Wide Association Data for Causal Protein Identification in Stroke

Identifying novel proteins for suicide attempt by integrating proteomes from brain and blood with genome-wide association data

Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease

Exploration of potential therapeutic targets for stroke based on the GEO database

Integrating machine learning and single-cell transcriptomic analysis to identify potential biomarkers and analyze immune features of ischemic stroke

Exploring biomarkers for ischemic stroke through integrated microarray data analysis

An integrated brain-specific network identifies genes associated with neuropathologic and clinical traits of Alzheimer’s disease